Catalent– tag –
-
CDMOs Overcome Multispecific Manufacturing Challenges with Continuous Bioprocessing and Catalent’s GPEx® Lightning Platform
BioSpace Unknown Overview Contract Development and Manufacturing Organizations (CDMOs) confront complex challenges in cell line development, analytical characterization, and downstream purification for multispecific molecules. To overcom... -
CDMOs Accelerate GLP-1 Manufacturing, Outpacing Traditional Facility Builds to Meet Soaring Demand
Pharma Advancement USA Overview Contract Development and Manufacturing Organizations (CDMOs) are rapidly scaling their manufacturing capabilities for GLP-1 receptor agonists, providing quicker solutions than ground-up facility constructi... -
Gene Therapy Manufacturing: Viral Vector CDMOs Confront Oversupply Amidst Rapid Expansion
IntuitionLabs USA Overview A recent industry report offers a comparative analysis of the AAV and lentiviral vector CDMO market, revealing trends of consolidation and emerging capacity oversupply. It highlights key players like FUJIFILM D... -
Scalable Automation in Adherent-Cell Cultures Boosts Yield and Quality: Corning’s HYPERStack and CellCube Systems Key to Efficiency
BioProcess International USA Overview Automation in scaling out adherent cell cultures significantly enhances consistency, proving especially effective where labor and bioprocessing expertise are limited. Automated culture platforms impr... -
Catalent Bolsters End-to-End CDMO Services for Autologous & Allogeneic Cell Therapies, Including iPSC Center of Excellence
Catalent USA Overview Catalent is enhancing its end-to-end CDMO manufacturing support and process development services for both autologous and allogeneic cell therapies, covering CAR-T, TCR, TIL, NK cells, and iPSC- and MSC-derived treat... -
Fujifilm Diosynth Commits $2 Billion to North Carolina Gene Therapy Facility Amid Supply Chain Shifts; India Emerges as Key CDMO Hub
BioSpace Global Overview Fujifilm Diosynth is investing approximately $2 billion in a new gene therapy manufacturing facility in North Carolina, strategically positioning against global supply chain shifts. Catalent, under Novo Holdings,... -
SNS Insider Analysis: Viral Vector Manufacturing Market Surges as Leading CDMOs Expand Capacity with Advanced AAV and Lentiviral Technologies
SNS Insider India Overview SNS Insider's market overview highlights that the increasing number of gene therapy clinical trials and the reliance on CDMOs are driving growth in the viral vector manufacturing market. Key CDMOs like Fujifilm... -
Lonza, Samsung Biologics, and Catalent Lead 2026 Biologics CDMO Market, Driven by AI Manufacturing & APAC Expansion
Towards Healthcare Unknown Overview Lonza, Samsung Biologics, and Catalent are identified as key players leading the 2026 biologics CDMO market. Lonza excels in end-to-end multi-modality and scientific innovation, Samsung Biologics in la...
1